The incidence of venous thromboembolic (VTE) events (deep vein thrombophlebitis [DVT] or pulmonary embolism [PE]) in foot and ankle trauma has been low, and the risk/benefit ratio associated with chemoprophylaxis is controversial. We compared the 90-day incidence of VTE events in 3 cohorts: group 1, tendo-Achillis (TA) ruptures managed with full weightbearing in a walker boot; group 2, ankle fractures immobilized non-weightbearing in a below-the-knee cast; and group 3, ankle fractures managed surgically, followed by non-weightbearing in a below-the-knee cast. Data were extracted from 2 prospectively collected trust databases for acute TA ruptures and ankle fractures. VTE risk was assessed using a U.K. national assessment tool. Chemoprophylaxis was prescribed for high-risk patients. The 90-day incidence of symptomatic VTE events was drawn from a trust-wide radiology database. In group 1 (n = 291), the incidence of VTE events was 4.8% (11 [3.8%] DVT, 3 [1.0%] PE) at a mean of 16.1 ± 6.8 days. In group 2 (n = 227), the incidence of VTE events was 2.2% (5 [2.2%] DVT) at a mean of 33.4 ± 11.3 days. In group 3 (n = 199), the incidence of VTE events was 3.0% (5 [2.5%] DVT, 1 [0.5%] PE) at a mean of 37.2 ± 14.2 days. Patients with symptomatic VTE events presented significantly earlier after acute TA rupture compared with after ankle fracture (p = .002). We found the overall incidence of VTE events in foot and ankle trauma was low, with a relatively greater incidence of symptomatic VTE events, which occurred earlier, in acute TA ruptures compared with ankle fractures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/j.jfas.2017.10.036 | DOI Listing |
Res Pract Thromb Haemost
January 2025
Department of Internal medicine, Ramathibodi Hospital, Mahidol University, Thailand.
Background: Reduced-dose anticoagulant therapy for extended treatment of cancer-associated venous thromboembolism (VTE) has been used to avoid bleeding. However, it may increase the risk of recurrent VTE.
Objectives: To study the rate of recurrent VTE and bleeding complications in Thai patients with cancer-associated VTE who were treated with full-dos/e or reduced-dose anticoagulants.
Pediatr Rheumatol Online J
January 2025
Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Besevler, 06500, Turkey.
Background: Pediatric patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) are at an increased risk of arterial and venous thromboembolism (AVTE). Although the exact mechanisms underlying AVTE remain unclear, eosinophils play a pivotal role in AVTE.
Main Body: Current guidelines lack evidence-based recommendations, particularly concerning anticoagulant and antiplatelet treatments for this condition.
Obstet Gynecol
January 2025
Rutgers New Jersey Medical School, Newark, New Jersey; the Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York; and the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California.
Objective: To assess trends in risk for obstetric venous thromboembolism (VTE).
Methods: This retrospective cohort study analyzed data from the 2008-2019 Merative MarketScan Commercial Claims and Encounters and Medicaid Multi-State databases. Women aged 15-54 years with a delivery hospitalization and health care enrollment from 1 year before pregnancy to 60 days after delivery were identified.
Cureus
December 2024
Orthopaedics, University of Central Florida, Orlando, USA.
Objective This study aims to utilize the TriNetX database, a comprehensive global network, to improve our understanding of the frequency, demographic factors, and related comorbidities of surgical patients who develop venous thromboembolism (VTEs) events. Methods The global collaborative network in TriNetX was queried for all cases from January 1, 2017, through December 31, 2023. International Classification for Disease (ICD) diagnosis codes were used to define patient cohorts with deep vein thrombosis (DVT) of the upper or lower extremity or pulmonary embolism (PE).
View Article and Find Full Text PDFIn Vivo
December 2024
Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, Geneva, Switzerland;
Background/aim: Low molecular weight heparin (LMWH) is widely employed to prevent postoperative venous thromboembolism (VTE). This study aimed at analyzing LMWH use and evaluating its efficacy and safety in immediate implant-based post-mastectomy breast reconstruction.
Patients And Methods: A monocentric retrospective analysis was conducted on patients who underwent immediate implant-based breast reconstruction (IBR) from January 2021 to December 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!